Dr. Inbar Maymon Pomeranchik appointed as independent board member of Cannabics Pharmaceuticals

CNBX Pharmaceuticals Inc.

Dr. Inbar Maymon-Pomeranchik, 43, appointed to board effective July 1, 2021.
Holds a PhD in molecular biology from Hebrew University, postdoc from Weizmann Institute, with 20 years exec experience in biotech and global medical cannabis.
Currently serves as founder & CEO of AgChimedes Group, founder of BioDiligence, Executive Director of Ananda Developments, Director of NRGene, and Advisory Board member of Avida Global.
Appointment was unanimously approved by the Board of Directors on July 1, 2021.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Inbar Maymon Pomeranchik

Independent Board Member

CNBX · CNBX Pharmaceuticals Inc.

Effective: 2021-07-01
Filed: July 6, 2021, 7:59 PM ET

On July 1 st , 2021, the Board of Directors appointed Dr. Inbar Maymon Pomeranchik as an Independent Board Member.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Inbar Maymon Pomeranchik was appointed as Independent Board Member at CNBX Pharmaceuticals Inc..

Action: appointed
Role: Independent Board Member

Exact text from the filing

On July 1 st , 2021, the Board of Directors appointed Dr. Inbar Maymon Pomeranchik as an Independent Board Member.

View on SEC.gov

CNBX Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001683168-21-002832

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.